For most of the last century, breast cancer was categorized only by its location in the body; as a result, treatment results varied significantly. Patients with metastatic HER2+ breast cancer were traditionally treated with conventional chemotherapy regimens until trastuzumab became available. In September 1998, the FDA approved Roche and Genentech’s breast cancer therapy, HERCEPTIN, as a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel, for the adjuvant treatment of HER2-positive node-positive breast cancer. Later in 2000, the European authority and in 2001, the Japanese Ministry of Health, Labor and Welfare approved HERCEPTIN in metastatic ...
